This funding builds on JDRF's previous support of the work of Dr. Michael Riddell of York University and Dr. Richard Liggins of The Centre for Drug Research and Development, founding scientists behind Zucara.
Zucara is advancing a novel therapeutic approach to prevent hypoglycemia in patients with diabetes. With this new investment, the company will be in a position to advance its lead clinical drug candidate through IND-enabling studies, readying it for clinical testing beginning in 2019.
The Zucara technology is aimed at creating the first treatment to prevent dangerous low blood sugar by restoring the body's ability to counter-regulate hypoglycemia. This approach will reduce the likelihood of insulin therapy to cause hypoglycemia without affecting its efficacy.
The immediate patient benefits would include the reduced occurrence of hypoglycemia and its associated acute symptoms and effects. This in turn would allow those with T1D to better regulate their blood sugar levels with insulin, resulting in better overall health outcomes in the long term.
JDRF funds T1D research to accelerate breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, the organization has invested more than USD2 bn in research funding since inception. It has staff and volunteers throughout the United States and at six international affiliates.
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development and MaRS Innovation, is developing a drug therapy to prevent hypoglycemia in people with diabetes.
The company's first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in Type 1 diabetes.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study